About omeros corporation - OMER
Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
OMER At a Glance
Omeros Corp.
The Omeros Building
Seattle, Washington 98119
| Phone | 1-206-676-5000 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -3,350,000.00 | |
| Sector | Health Technology | Employees | 175 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
OMER Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.884 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.307 |
OMER Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -19,142.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
OMER Liquidity
| Current Ratio | 2.763 |
| Quick Ratio | 2.763 |
| Cash Ratio | 2.201 |
OMER Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -1.595 |
| Return on Equity | N/A |
| Return on Total Capital | -1.682 |
| Return on Invested Capital | -2.211 |
OMER Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 142.421 |
| Total Debt to Total Assets | 124.99 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 127.056 |